Sage's seizure treatment leads to 73% ORR

Sage Therapeutics Inc. (NASDAQ:SAGE) said its SAGE-547 led to a 73% overall response rate in a Phase I/II trial to treat super-refractory status epilepticus (SRSE).

The study enrolled 12 adults who had been in a state of persistent seizure for at least 24 hours and who had one or more breakthrough seizures at least six hours after they were given a third-line anesthetic. Of the 11 evaluable patients who were given SAGE-547 continuously for five days, eight were weaned off their anesthetic agents. Those eight patients were then weaned off SAGE-547 without recurrence of SRSE. ...